Table 1 Characteristics of 311 individuals included in the analyses
From: FEV1 and FVC and systemic inflammation in a spinal cord injury cohort
Characteristic | Mean ± SD or Median (25th percentile – 75th percentile) |
|---|---|
Age (yrs) | 54.0 ± 14.1 |
Body mass index (kg/m2) | 26.9 (22.8–31.2) |
Injury duration (yrs) | 14.1 (5.3–25.4) |
Pack years of smokinga | 18.0 (5.0–37.2) |
CRP (mg/L) | 2.4 (1.0–6.9) |
IL-6 (pg/mL) | 2.1 (1.3–4.4) |
FEV1 (L) | 2.8 ± 0.9 |
% predicted FEV1 | 77.6 ± 20.9 |
FVC (L) | 3.6 ± 1.1 |
% predicted FVC | 78.3 20.1 |
FEV1/FVC | 0.77 ± 0.11 |
Characteristic | N (%) |
 Males | 260 (83.6) |
 Race | |
  White | 282 (90.7) |
  African American | 23 (7.4) |
  Asian | 3 (1.0) |
  American Indian/Alaskan Native | 3 (1.0) |
 Level of injury | |
  Motor complete cervical & AIS C | 76 (24.4) |
  Motor complete high thoracic & AIS C | 42 (13.5) |
  Motor complete low thoracic & AIS C | 61 (19.6) |
  All AIS D | 132 (42.4) |
 Mobility mode | |
  Motorized wheelchair | 60 (19.3) |
  Wheelchair | 135 (43.4) |
  Walk with cane/walker | 54 (17.4) |
  Walk unassisted | 62 (19.9) |
 Cigarette smoking status | |
  Current | 52 (16.7) |
  Former | 132 (42.4) |
  Never | 127 (40.8) |
 Marijuana smoking status | |
  Current | 37 (11.9) |
  Former | 38 (12.2) |
  Never | 236 (75.9) |
 Current statin use | 97 (31.2) |
 Any pulmonary medication use | 19 (6.1) |
 Short-acting bronchodilator within 6 h | 3 (1.0) |
 Long-acting bronchodilator within 24 h | 13 (4.2) |
 Current inhaled/oral steroid use | 16 (5.1) |
 Doctor diagnosed COPD or asthma | 30 (9.7) |
 History of chest operation or injury | 90 (28.9) |